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Article
Identification of anticancer drugs for hepatocellular
carcinoma through personalized genome-scale
metabolic modeling
Rasmus Agren1,†, Adil Mardinoglu1,†, Anna Asplund2, Caroline Kampf2, Mathias Uhlen3,4 &
Jens Nielsen1,3,*
Abstract
Genome-scale metabolic models (GEMs) have proven useful as
scaffolds for the integration of omics data for understanding the
genotype–phenotype relationship in a mechanistic manner. Here,
we evaluated the presence/absence of proteins encoded by 15,841
genes in 27 hepatocellular carcinoma (HCC) patients using
immunohistochemistry. We used this information to reconstruct
personalized GEMs for six HCC patients based on the proteomics
data, HMR 2.0, and a task-driven model reconstruction algorithm
(tINIT). The personalized GEMs were employed to identify
anticancer drugs using the concept of antimetabolites; i.e., drugs
that are structural analogs to metabolites. The toxicity of each
antimetabolite was predicted by assessing the in silico functionality
of 83 healthy cell type-specific GEMs, which were also recon-
structed with the tINIT algorithm. We predicted 101 antimetab-
olites that could be effective in preventing tumor growth in all
HCC patients, and 46 antimetabolites which were specific to
individual patients. Twenty-two of the 101 predicted antimetabo-
lites have already been used in different cancer treatment
strategies, while the remaining antimetabolites represent new
potential drugs. Finally, one of the identified targets was validated
experimentally, and it was confirmed to attenuate growth of the
HepG2 cell line.
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Introduction
Hepatocellular carcinoma (HCC) is the most common form of
primary liver cancer and affects more than half a million people
worldwide, with the highest incidences in Asia and Africa (Jemal
et al, 2011). It is the third leading cause of cancer death, and the
global burden of HCC continues to increase worldwide (Finn, 2010).
Multiple etiologic factors are implicated in the development of HCC
(Sanyal et al, 2010), and these factors have a direct impact on
patient characteristics as well as the tumor progression. The treat-
ment of an HCC patient is dependent on the size, stage, and grade of
the tumor, and several treatment modalities are available, including
liver transplantation and local ablative therapies (Padhya et al,
2013). There is an urgent need for the development of efficient
drugs since sorafenib, an approved drug for HCC, is effective only in
approximately 30% of the patients (Bruix & Sherman, 2011). The
diagnosis of HCC still remains difficult and there are large gaps in
our current understanding about the underlying molecular mecha-
nisms involved in the pathogenesis of HCC (Sanyal et al, 2010). The
elucidation of these diverse mechanisms for the identification of
novel drug targets has therefore been a major focus in medicine,
and further research efforts are still needed for an increased under-
standing and for developing efficient treatment strategies. However,
this is quite a challenging task, since HCC involves a large number
of interplays between different biological pathways (Ye et al, 2012).
In addition to environmental factors, individual genetic variations
should also be accounted for developing effective treatment strate-
gies and for optimizing surveillance methods. This could be
achieved through personalized medicine (Chen et al, 2012; Hood
et al, 2012), a novel approach to healthcare that allows to tailor the
treatment strategy based on the individual’s genetic makeup (Hood
& Friend, 2011).
The decreasing cost of omics profiling has made high-throughput
technologies available for understanding the molecular basis
of disease. Genome-scale metabolic models (GEMs) can aid in
this by providing a scaffold for the integration of omics data
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(Mardinoglu & Nielsen, 2012). To date, different generic human
GEMs (Duarte et al, 2007; Mardinoglu et al, 2013a, 2014; Thiele
et al, 2013) have been reconstructed. These models can be success-
fully employed to gain further biological and mechanistic under-
standing of metabolism-related diseases, discovering potential
biomarkers and identifying novel drug targets (Mardinoglu et al,
2013b; Va¨remo et al, 2013). Furthermore, different GEMs for cancer
have been reconstructed to characterize the genetic mechanisms of
cancer and to reveal how cancer cells benefit from metabolic modifi-
cations (Folger et al, 2011; Frezza et al, 2011; Agren et al, 2012). In
particular, Folger et al (2011) predicted 52 potential cytostatic anti-
cancer drug targets and synthetic lethal gene targets through gene
knockdowns by employing a generic cancer GEM.
Cancer cells proliferate rapidly and adapt their metabolism based
on the availability of nutrients necessary for the synthesis of new
building blocks, a feature which is the basis for many of the antican-
cer drugs currently in use (Lazar & Birnbaum, 2012). One of the
most common types of anticancer drugs is antimetabolites which
prevent the use of one or more endogenous metabolites by inhibit-
ing the catalyzing enzymes, normally by being structurally similar
to the metabolite(s) in question. Examples of such antimetabolites
are antifolates and antipurines, which mimic folic acid and purines,
respectively. This type of drugs has been used for decades and
results in disrupted robustness of the cancer cell and reduction or
suppression of growth (Garg et al, 2010; Hebar et al, 2013). The
purpose of this study was to predict potential antimetabolites (or
rather, their corresponding endogenous metabolites) for HCC by
simulating their effect using genome-scale metabolic modeling.
In this study, we first evaluated the presence/absence of proteins
encoded by 15,841 genes in tumors obtained from 27 HCC patients
(Fig 1A) and identified extensive differences between six HCC
patients based on the proteomics data. Secondly, we developed the
tINIT (Task-driven Integrative Network Inference for Tissues) algo-
rithm, which allows for automated reconstruction of functional
GEMs based on protein evidence and a novel task-driven recon-
struction approach (Fig 1B). To this end, we defined a set of core
metabolic tasks that should occur in all cell types and enforced their
functionality during the GEM reconstruction process. Thirdly, we
applied tINIT to the Human Metabolic Reaction database (HMR) 2.0
(Mardinoglu et al, 2014) together with personalized proteomics data
and reconstructed functional personalized GEMs for six HCC
patients. Fourthly, we generated functional GEMs for 83 different
healthy cell types based on the proteomic data in the Human Protein
Atlas (HPA, www.proteinatlas.org). This approach represents a
significant step forward in the reconstruction of cell type-specific
models, given that tINIT not only generates connected and consis-
tent metabolic networks, but also ensures functionality by integrat-
ing evidence-based metabolic functions which are established for a
certain cell type. Furthermore, we identified potential antimetabo-
lites that were predicted to inhibit or kill the growth of HCC tumors
in all six patients (Fig 1C). Since the inhibition of a metabolite may
lead to abnormalities in the metabolic functions of a healthy cell,
the toxic effect of each antimetabolite was evaluated for a number
of metabolic tasks in each of the 83 healthy cell type GEMs. The
proposed antimetabolites are therefore likely to damage the tumor
in all HCC patients, with the least possible side effects on the func-
tion of other healthy cell types (i.e., having high efficacy and low
toxicity). Finally, we experimentally evaluated the effect of an
L-carnitine analog, one of the predicted antimetabolites for the inhi-
bition of HCC tumor growth in all patients. By evaluating prolifera-
tion of HepG2 cell lines in the presence or absence of the analog,
we could confirm our genome-scale modeling predictions. The
presented method allowed for the identification of potential thera-
peutic targets for treatment of HCC by considering individual differ-
ences in protein expression patterns and may therefore aid in filling
the existing gap between proteomics and drug discovery.
Results
Personalized proteome data for HCC patients
The presence/absence of proteins encoded by 15,841 genes (Supple-
mentary Dataset S1) in HCC tumor obtained from 27 male and
female HCC patients (Supplementary Dataset S2) was evaluated
using 18,707 antibodies generated in the HPA project. Duplicate
evaluations of every protein were performed, and the abundance of
each protein was analyzed in three or more HCC patients. The
proteomics data displayed notable differences between the 27 HCC
patients during the determination of the global protein expression
levels (Fig 2A).
Here, we focused on the proteomics differences of six HCC
patients that had the largest coverage of protein expression levels
(Fig 2B). The number of the evaluated proteins in these HCC patients
varied between 9,312 and 14,561. The expression levels of 4,936
proteins were identified in all six HCC patients and healthy hepato-
cytes (Fig 2C and Supplementary Dataset S3). Figure 2C demon-
strates the apparent differences between the proteomics data of the
HCC tumors and with the healthy hepatocytes. Functional differ-
ences between these 4936 proteins were identified through the level
5 gene ontology biological process (GO BP) terms (Supplementary
Dataset S4) using DAVID (Huang et al, 2009) and GO BP terms with
adjusted P-values < 0.005 are presented in Supplementary Fig S1.
In order to reconstruct personalized GEM for the six HCC
patients based on the proteomics data, the missing expression of
protein in each patient was predicted based on the protein expres-
sions in the other 26 HCC patients. Hereby, the absence/presence of
15,841 proteins could be evaluated in the six HCC patients (Supple-
mentary Dataset S5) and these proteomics data for each HCC patient
were used for the reconstruction of personalized GEMs. The func-
tional differences of the proteomics data were also identified
through GO BP terms (Supplementary Dataset S6) using DAVID
(Huang et al, 2009) and GO BP terms with adjusted
P-values < 0.0001 are presented in Supplementary Fig S2. It is
observed that there are significant differences in GO BP terms
between the hepatocytes and the HCC patients. In particular, GO BP
terms including positive regulation of programmed cell death, posi-
tive regulation of apoptosis, mitosis, M phase of mitotic cell cycle,
protein catabolic process, fatty acid (FA) catabolic process, FA
oxidation and lipid oxidation showed notable changes in all HCC
patients compared to healthy hepatocytes.
Personalized GEMs for HCC patients
It is known that the synthesis, degradation, and redistribution of
metabolites and minerals as well as metabolite consumption rates
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are different in cancer versus normal cell types (Lazar & Birnbaum,
2012). We have previously developed the INIT algorithm and used
it to reconstruct active metabolic networks for 69 cell types and 16
cancers (Agren et al, 2012). We identified the common metabolic
differences between cell types and cancers using the reconstructed
model. These networks could be seen as snapshots of active metab-
olism in a given cell type, but they were not functional models that
could be directly applied for simulations. Recently, we constructed
HMR 2.0 (Mardinoglu et al, 2014), which contains 8,181 reactions,
6,007 metabolites in eight different compartments, and 3,765 genes
associated with the reactions (Table 1).
Here, we reconstructed personalized GEMs for six HCC patients
based on personalized proteomics data and HMR 2.0 by employing
the new concept of task-driven model reconstruction (Fig 1B). This
was done by first defining a list of 56 metabolic tasks which must
occur in all cell types and that the resulting model should be able to
perform (Supplementary Dataset S7). Literature evidence for
the occurrence of these tasks in all human cells is provided in
83 Healthy cell-types6 HCC Patients
Cell type GEMsPersonalized GEMs
Human metabolic reaction (HMR) 2.0 database
Antimetabolites for HCC
 27 HCC patients 
 83 healthy cells 
 56 metabolic tasks 
 Growth in HCC tumours 
tINIT AlgorithmHuman Protein Atlas
Toxicity TestAntimetabolites
A  B  
101 Antimetabolites
C  
Effect of antimetabolites on healthy 
cell types 
 Failing of  the 56 metabolic tasks 
P1 P2 P3 
P4 
P6 
P5 
P8 
P2 
P9 Blocked reaction 
Antimetabolite 
Other metabolite 
Protein P 
A B 
D E 
C 
 Testing of 3,160 metabolites 
 High efficacy (410) 
High efficacy in all six HCC 
patients (349) 
 Pool metabolites are ignored 
Figure 1. General pipeline for the identification of antimetabolites.
A The presence/absence of 15,841 proteins in tumors obtained from 27 HCC patients was evaluated using immunohistochemistry. tINIT algorithm was developed and
used for reconstruction of personalized GEMs for six HCC patients and GEMs for 83 healthy cell types based on proteomics data and HMR 2.0. A method identifying
potential antimetabolites for the treatment of the HCC patients was developed, and the toxicity of each antimetabolite was predicted using GEMs for healthy cells
types.
B tINIT was used for reconstructing GEMs which are in agreement with omics data and which could perform a set of predefined tasks. In this illustration, the model
should perform two simple tasks; production of “D” from “A” and “E” from “B.” The resulting model should contain as many of the green reactions and as few of the
red ones as possible. In the first step, all reactions were identified which, if removed from the network, cause any of the tasks to fail. These reactions were marked
blue. In the second step, the INIT algorithm was used to find the network with the maximal number of green reactions compared to red, with the additional
constraints that the model must be functional and that all blue reactions must be included. This would result in the dotted reactions being removed from the
network. At this stage, the first task would be possible, but not the second one (since uptake of “C” makes the production of “E” possible without using any red
reactions). In the final step, each task was tested and a gap-filling algorithm was used to reinsert the reactions which were required for all tasks to work. This would
result in the inclusion of the lower-most red reaction.
C The effect of antimetabolites can be predicted in silico by using metabolic network and potential use of antimetabolites is illustrated.
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Supplementary Dataset S7. These 56 metabolic tasks were catego-
rized as energy and redox, internal conversions, substrate utilization
and biosynthesis of products. Examples include the catabolism of
nutrients or biosynthesis of precursors, but also generation of
membrane potentials and ADP re-phosphorylation. For cancer cells,
biomass growth was also included as an extra metabolic task. The
objective was then to reconstruct models that can perform all the
defined tasks and at the same time are consistent with the proteo-
mics data. This concept was formulated in the tINIT algorithm (see
Materials and Methods) and implemented in the RAVEN Toolbox
(Agren et al, 2013).
Personalized GEMs for the HCC patients are provided in SBML
format at the Human Metabolic Atlas (HMA) portal (www.metabol-
icatlas.org), and the contents of the models are presented
(Table 1). The resulting personalized models ranged in size from
4,690 to 4,967 reactions and 1,715 to 2,025 genes. A total of 5,405
reactions and 2,361 genes were shared across the models and 4,212
of the reactions and 1,324 of the genes were present in all six
personalized HCC models. It was observed that 248 of the reactions
(Supplementary Fig S3A), 102 of the metabolites (Supplementary
Fig S3B), and 227 of the genes (Supplementary Fig S3C) were
unique to any one model. However, we observed notable differ-
ences between the reactions (Fig 3A) and genes (Fig 3B) during a
pairwise comparison of the models. The differences between the
numbers of reactions in the personalized models varied between
356 and 610, whereas the similarities between the reactions varied
between 4,437 and 4,699. On the other hand, we observed larger
differences in the number of the genes incorporated into the
B 
CA
Figure 2. Proteomics data for 27 HCC patients.
A Clustering of the generated proteomics data between 27 different HCC patients showed notable differences. The color indicates the protein expression differences
between tissue samples.
B Due to the coverage of the proteomics data, we focused on the reconstruction of the personalized models for six HCC patients. The number of the evaluated proteins
in each HCC patients varies between 9,312 and 14,561.
C The expression level of 4,936 proteins measured in all six HCC patients and the proteomics data showed notable differences between the HCC patients and
hepatocytes.
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models. The model differences on the present genes varied between
392 and 524, and considering all 2,361 genes shared in all models,
a 16–22% difference was observed between the personalized
models.
To investigate to which extent the personalized HCC models
differ from a HCC population model, we reconstructed a generic
HCC model based on the average protein expression of the 27 HCC
patients and presented the content of the generic HCC model in
Table 1. The pairwise reaction and gene differences between the
personalized models and generic HCC model are also presented in
Fig 3A and B, respectively. As it can be seen, the generic HCC model
is about as different to the personalized models as these models are
to one another.
In order to check whether a specific pathway is activated in the
personalized and generic HCC models, we counted the number of
the reactions in the relevant subsystem of HMR 2.0 (Supplementary
Dataset S8). The numbers of the reactions in the personalized and
generic HCC models did not show any significant differences. We
further observed that none of the specific pathways were activated
or deactivated in each of the personalized and generic HCC models.
However, in-depth analysis showed that many reactions in the
specific pathways differed between the models, and hence, this
Table 1. The content of the HMR 2.0, generic HCC model, and personalized genome-scale metabolic models for six HCC patients
Reactions Metabolites Genes Model-specific reactions Model-specific metabolites Model-specific genes
Generic human model
HMR 2.0 8181 6007 3765 – – –
Generic HCC model
HCC average model 4816 4346 1779 – – –
Personalized models for HCC patients
Patient 2177 4823 4339 1823 29 9 21
Patient 2280 4954 4446 2025 89 49 74
Patient 2556 4690 4324 1715 24 7 25
Patient 2766 4967 4418 2009 36 8 57
Patient 3196 4764 4377 1860 39 19 26
Patient 3477 4833 4341 1803 31 10 24
Common in all models 4212 4113 1324 – – –
Total shared components 5405 4599 2361 – – –
BA
Figure 3. Comparison of the personalized GEMs for HCC patients.
A, B The pairwise differences and similarities of the reactions (A) and genes (B) between personalized HCC models and the generic HCC model that is reconstructed
based on the average protein expression level of 27 HCC patients.
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shows that different enzymes are activated in the different cancers
but the same overall metabolic functions are characteristic of HCC.
Cell type-specific functional GEMs
We reconstructed functional GEMs for 83 healthy cell types based
on HMR 2.0 using tINIT algorithm. The proteomics data in HPA
version 12.0, as well as the list of 56 metabolic functions known to
occur in all cell types, were used as input to tINIT to generate func-
tional cell type GEMs. The GEMs are available in SBML format at
the HMA portal (www.metabolicatlas.org). The number of the
reactions, metabolites, and genes in the models are presented in
Supplementary Dataset S9. These models represent a significant
improvement over existing automatically reconstructed cell type-
specific models in that they are based on high-quality proteomics
data and are built to carry out a range of important metabolic func-
tions. This makes them an important resource to perform simula-
tions or for the integration of omics data.
Antimetabolites for HCC patients
Previously, Kim et al (2011) used the concept of metabolite essenti-
ality to identify potential drug targets using a GEM for an opportu-
nistic microbial pathogen. The targets were then used to identify
novel potential antimicrobial targets from a chemical library, and a
screening identified one chemical to have clear antimicrobial prop-
erties. The concept of metabolite essentiality is a similar approach
to that of antimetabolites. An antimetabolite is structurally similar
to a specific metabolite, but it cannot be utilized for the production
of physiologically important substances. Its drug action comes from
that it inhibits or otherwise affects the enzyme(s) that utilizes the
metabolite. A strong characteristic of antimetabolites is that they
can allow for targeting of multiple enzymes simultaneously and
can reduce or kill the growth of tumors more effectively (Garg
et al, 2010). Antimetabolites is one of the most widely used type of
drugs for cancer treatment as of today (Hebar et al, 2013). Since
antimetabolites accomplish their drug action from being structur-
ally similar to metabolites, here we emulate the effect of antimetab-
olites by inhibiting enzymes based on which metabolites they have
as substrates. We identified the metabolites that, upon blockage,
disabled tumor growth in HCC patients while having a minimal
effect on the previously defined biological processes of healthy
cells (Fig 1C) (see Materials and Methods). The structural analogs
of these metabolites were predicted as potential anticancer drugs
and proposed as antimetabolites. Such analogs can be screened
from chemical libraries in a similar manner to what was success-
fully used by Kim et al (2011) for the identification of novel
antibiotics.
By means of our approach, we predicted 147 antimetabolites that
can inhibit growth in any of the studied six HCC tumors (Supple-
mentary Dataset S10). One hundred and one (69%) of these poten-
tial antimetabolites were predicted to be effective in disabling
growth in all six HCC patients (Fig 4A), 23 (16%) of the antimetabo-
lites were effective in 2–5 patients, and the remaining 23 (16%) of
the antimetabolites were only effective in one of the patients
(Fig 4B). The 46 (31%) of the antimetabolites that are predicted to
be effective in only some of the HCC patients are presented in
Fig 4C. Even though 69% of antimetabolites disable growth in all of
the HCC tumors, the fact that not all antimetabolites are applicable
for all the HCC tumors illustrates the importance of using personal-
ized models rather than relying on a generic HCC model.
One hundred and one potential antimetabolites that were
predicted to be effective in all six HCC patients were grouped based
on the relevant subsystem in HMR 2.0 and literature evidence for
their usage as antimetabolites in different cancers was included
(Supplementary Dataset S11). The evidence for each metabolite was
provided for HCC and for other cancers if it has not been used in the
treatment of HCC yet. The number of antimetabolites in each
subsystem is presented in Fig 5. It was observed that cholesterol
biosynthesis contained the largest number of metabolites, followed
by synthesis of co-factors, nucleotides, lipids, amino acids, and
folate metabolism.
The analogs of 22 metabolites in folate, vitamin B12, and nucleo-
tide metabolism were proposed as antimetabolites for inhibiting or
killing the growth of tumors in all HCC patients. Vitamin B12 and
folate metabolism may induce abnormal DNA methylation and DNA
synthesis and the development of HCC is associated with an
increased DNA synthesis (Leong & Leong, 2005). Fourteen of these
metabolite analogs have already been used as antimetabolites in the
treatment of different types of cancer (Supplementary Dataset S11)
and the remaining eight metabolites were predicted to be beneficial
for inhibiting the growth since the enzymes utilizing these metabo-
lites have already been targeted in different cancers.
The analogs of 30 metabolites were targeting enzymes in the
cholesterol biosynthesis and mevalonate pathways. Cholesterol is
an essential molecule for building cell membranes and a precursor
to several essential hormones and bile acids. The growth of HCC
tumors is dependent on cholesterol biosynthesis (Borena et al,
2012), and use of statins that inhibit the enzyme HMG-CoA reduc-
tase has previously been proposed in the treatment of HCC (Lonardo
& Loria, 2012). Although HMG-CoA reductase is the rate-limiting
and key regulatory enzyme in the cholesterol synthesis, several
other enzymes in cholesterol biosynthesis have been targeted
for preventing the proliferation of the cells in different cancers
(Cuthbert & Lipsky, 1997) (Supplementary Dataset S11).
The analogs of 13 metabolites in terpenoid backbone biosynthe-
sis, two metabolites in pantothenate and CoA biosynthesis, one
metabolite in nicotinate and nicotinamide metabolism, two metabo-
lites in riboflavin metabolism, nine metabolites in lipid metabolism
and eight metabolites in amino acid metabolism were identified as
potential antimetabolites.
Two metabolites involved in the synthesis of tetrahydrobiopterin
(BH4), which is an essential cofactor for several aromatic amino
acid hydroxylases including tyrosine and tryptophan, were predicted
as antimetabolites. BH4 is synthesized from GTP and supplementa-
tion of the BH4 has been shown to increase cell proliferation and
effect tumor angiogenesis in endothelial cells (Chen et al, 2010).
One of these metabolite analogs has already been used as antime-
tabolite. Tyrosine was also among the proposed antimetabolites for
HCC, and tyrosine kinase inhibitors have been proposed as potential
targets for the treatment of HCC (Giannelli et al, 2007).
The analogs of eight metabolites were identified in heme and
porphyrin metabolism. The analog of 5-aminolevulinate, which can be
synthesized from glycine and succinyl CoA and is a precursor for the
synthesis of porphyrin, heme, and bile pigments (Ishizuka et al, 2011),
has already been used as an anticancer drug. The correlation between
Molecular Systems Biology 10: 721 | 2014 ª 2014 The Authors
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activity of the remaining seven metabolites and the cancer progression
was obtained in different cancers (Supplementary Dataset S11).
In summary, 22 of these 101 potential antimetabolites are in
current use as anticancer drug targets and 61 of them have either
been proposed as drug targets or show a strong correlation with
cancer progression. Eighteen of targets have not been previously
suggested as anticancer drugs. We also evaluated the toxic effect of
these potential antimetabolites using 83 GEMs for healthy cells for
testing the disruption of the antimetabolites on the healthy cell types
in human body.
We also predicted antimetabolites through the use of the generic
HCC model which was reconstructed based on the average HCC popu-
lation data. Analogs of 127 metabolites were predicted as antimetabo-
lites through the generic HCC model, and 26 (20%) of these
antimetabolites were not suitable for inhibiting the growth in all six
HCC patients (Fig 4A). These 26 antimetabolites would therefore not
be suitable targets for cancer treatment in all HCC patients. Thus,
personalized HCC models allowed us to predict the effect of these
false-positive antimetabolites on the treatment of all HCC patients. It
is hereby clear that the use of personalized models can significantly
improve the identification of drug targets effective in a given patient.
The potential use of L-carnitine analog in the treatment of HCC
The analogs of L-carnitine and metabolites involved in the synthesis
of L-carnitine were proposed as antimetabolites for the treatment of
all six HCC patients due to the non-toxic effect to here studied
healthy cell types (Fig 6). L-Carnitine is synthesized in the liver and
A
B
C
Figure 4. Prediction of antimetabolites for HCC patients.
A 147 antimetabolites are predicted as potential anticancer drugs through personalized HCC models and 101 of these antimetabolites are effective for inhibiting HCC
tumor growth in all six HCC patients. Antimetabolites are also predicted through the use of a generic HCC model that is reconstructed based on the average protein
expression data in HCC patients, and 127 potential antimetabolites are identified. Twenty-six of the antimetabolites predicted based on the generic HCC models are
not effective in all six HCC patients.
B Distribution of the antimetabolites that are predicted to be effective in number of the personalized HCC models.
C 46 of the antimetabolites identified through the use of personalized models cannot be used for inhibition of the HCC tumor in all six HCC patients. The differences
between the 46 predicted antimetabolites are shown through the use of personalized and generic HCC models.
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kidneys, from the essential amino acids lysine and methionine, but
it can also be derived from dietary sources (Rebouche, 1991). Nota-
bly, the analogs of lysine and methionine were also predicted as
antimetabolites through our analysis and have already been used as
antimetabolites in the treatment of different cancers. We also
observed that proteins involved in the synthesis of the L-carnitine
have strong or moderate expression levels in HCC tumors.
L-Carnitine has powerful antioxidant and anti-inflammatory prop-
erties and has a decisive role in the metabolism of FAs and energy
by regulating the free CoA and acyl-CoA ratio in the mitochondria
(Silverio et al, 2011). L-Carnitine is involved in the transport of acti-
vated long-chain FAs from the cytosol to the mitochondria where
these mobilized FAs can be degraded through b-oxidation. FAs
represent a very relevant energy source for many cells, including
cancers, and can be taken up from outside the cell, synthesized
through de novo synthesis or obtained through lipolysis in the liver.
L-Carnitine also facilitates the transfer of peroxisomal b-oxidation
products to the mitochondria and removal of medium-chain FAs.
Notably, our GO BP term enrichment analysis of hepatocytes and
HCC tumor proteomics data suggested that the expression level of
the genes involved in FA and lipid oxidation in HCC patients was
higher than in healthy hepatocytes. Higher protein expression level
of genes involved in b-oxidation can be explained by the increased
functional activity of mitochondria in HCC. Previously, Wu et al
(1984) measured the size, number, and surface membranes of the
mitochondria in HCC tumor and reported a significantly higher
activity of mitochondria. Furthermore, Toshima et al (2013) also
reported the activation of the b-oxidation in HCC progression. The
b-oxidation process provides ATP and also supplies and converts
nutrients in the liver (Carracedo et al, 2013).
In order to test the use of an L-carnitine analog as a potential
antimetabolite for the inhibition of HCC tumor growth, we studied
the effect of perhexiline, an inhibitor of carnitine palmitoyltransfer-
ase 1 (CPT1) and to a lesser extent CPT2, on the proliferation of the
HepG2 cell line. In our study, we used perhexiline to mimic the
effect of the L-carnitine analog since L-carnitine conjugates to FAs
and translocates them to the mitochondria through the enzyme
CPT1. We treated the HepG2 cells with four different concentrations
(2, 4, 8 and 20 lM) of perhexiline, determined the viable cells after
24 and 48 h, and compared the inhibitory effect of perhexiline to
sorafenib (2 and 4 lM) (Fig 7). Whereas the lower concentration
(2 lM) had no effect, the results clearly showed that the treatment
of the HepG2 cell line with 8 and 20 lM perhexiline reduced the
viability of the HepG2 cell line after 24 and 48 h (Fig 7A) and that
its effect is comparable to the effect of sorafenib (Fig 7B). Figure 7C
shows HepG2 cells after 24 h of treatment with 20 lM perhexiline.
Discussion
In order to reduce the public health burden of HCC, continued
efforts are needed to identify novel drug targets for developing effec-
tive HCC treatment strategies. It is well known that cancer cells
modify their metabolism in order to meet the requirements of
cellular proliferation. The potential use of metabolic enzymes as
therapeutic targets has led to a renewed interest in understanding
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
Vitamin B12 metabolism 
Tyrosine metabolism 
Terpenoid backbone biosynthesis 
Sphingolipid metabolism 
Riboflavin metabolism 
Porphyrin metabolism 
Pantothenate and CoA biosynthesis 
Nucleotide metabolism 
Nicotinate and nicotinamide metabolism 
Lysine metabolism 
Lipoic acid metabolism 
Glycine, serine and threonine metabolism 
Glycerophospholipid metabolism 
Folate metabolism 
Cysteine and methionine metabolism 
Cholesterol biosynthesis 
Biopterin metabolism 
Used as AM 
Same enzymes targeted, but with other AM 
Same enzymes targeted, but not with AM 
Same metabolite/enzyme targeted, but at least partly for other reasons 
AM developed for other conditions than cancer 
Activity correlates with cancer progression 
Figure 5. Evidence levels of the predicted antimetabolites for HCC patients.
Antimetabolites are a type of drugs, which acts by inhibiting the use of a normal metabolite, most often by being structurally similar to the metabolite in question. The 101
predicted antimetabolites were categorized based on their known use as antimetabolites and/or their connection to HCC (see Supplementary Dataset S11 for literature
evidence). In summary, 22 of the predicted antimetabolites are currently in use as anticancer drugs, and 9 are used as drugs against other diseases. For 39 of them, the
corresponding enzymes are currently targets for drugs but not with antimetabolites. The remaining 31 have not been investigated as drugs or drug targets, but all of them
show a strong correlation with cancer progression. These results speak strongly for the validity of the in silico predictions.
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the altered metabolism in cancer (Vander Heiden, 2011). Our study
showed a novel approach to identify therapeutic targets for treating
HCC through combination of personalized proteomics data and
metabolic modeling. This is the first time personalized GEMs have
been used to find and evaluate new potential drugs, some that could
be used for general treatment of HCC, and others that are highly
specific for each HCC patient.
We generated high-quality personalized proteomics data for 27
HCC patients in order to understand the differences in tumor
appearance and to search for potential drugs that would be effective
in all patients. We developed the tINIT algorithm and reconstructed
personalized GEMs for six HCC patients based on the personalized
proteomics data and HMR 2.0. The tINIT algorithm was developed
for the efficient reconstruction of simulation-ready models based on
omics data coupled with defined metabolic tasks.
In a similar fashion, we also reconstructed functional cell type-
specific GEMs for 83 different healthy cell types, which represent an
important resource in their own. These functional GEMs may enable
the application of constraint-based modeling techniques to distin-
guish metabolic states under different physiological conditions.
This is a significant improvement over the previous automatically
reconstructed GEMs, since these functional models were generated
based on high-quality proteomics data and in a manner that enables
them to perform a range of defined biological tasks. These tasks can
of course be expanded on, and functional models for other cell types
can be reconstructed with the tINIT algorithm as implemented in
the RAVEN Toolbox (Agren et al, 2013).
By using the concept of antimetabolites, we were able to propose
anticancer drugs which could be effective in inhibiting tumor
growth. Furthermore, we simulated the effect of these antimetabo-
lites on 83 healthy cell types to predict their toxic effects. We thus
identified 101 antimetabolites which were predicted to inhibit
cancer growth in all six HCC patients simultaneously, while not
being overly toxic to healthy cells. Through our personalized model-
ing approach, we also predicted 46 antimetabolites which would
inhibit HCC tumor growth only in a subset of the patients. There-
fore, the outcome of our study can be used to predict false-positive
drug targets that would not be effective in all patients.
One of the few identified antimetabolites that have not yet been
studied for cancer patients is antimetabolites of L-carnitine. We
predicted that such antimetabolites may inhibit the b-oxidation and
hereby suppress the growth of HCC tumor (Fig 6). This was tested
Figure 6. Usage of L-carnitine antimetabolites for the treatment of HCC.
L-Carnitine and metabolites in the L-carnitine biosynthetic pathway, as well as two essential amino acids, lysine and methionine, necessary for the synthesis of L-carnitine
were identified through our modeling approach. The analogs of L-carnitine were proposed as antimetabolites for the treatment of HCC patients and the predicted
consequence of the use of an L-carnitine antimetabolite is presented. L-Carnitine antimetabolites may result in reduced b-oxidation, de novo synthesis of fatty acids, and
eventually may suppress or kill the growth of the HCC tumor. The abbreviations and the detailed explanations for the metabolites as well as the associated genes for each
reaction are presented in HMR 2.0.
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in vitro using perhexiline, which has been used to mimic the
behavior of an L-carnitine analog, and it was shown to reduce the
viability of HepG2 cells. This is a proof of principle that genome-
scale modeling can be used to predict relevant targets for anticancer
drug identification.
Several other studies have also proven the link between b-oxida-
tion and different types of cancer and support our here presented
results. b-Oxidation is a central pathway for energy generation in
prostate cancer (Liu, 2006), and enhanced mitochondrial b-oxida-
tion has been associated with tumor promotion in pancreatic cancer
(Khasawneh et al, 2009). Inhibition of b-oxidation has been shown
to induce apoptosis in leukemia cells and in glioblastoma cells
(Samudio et al, 2010; Pike et al, 2011). It is earlier reported that
expression of CPT1C, a brain-specific enzyme, in cancer cells
promoted FA oxidation, ATP production, resistance to glucose
deprivation, and tumor growth (Zaugg et al, 2011). The expression
of CPT1C, which is frequently up-regulated in human lung tumors,
increased the resistance to the mTOR complex 1 (mTORC1) inhibi-
tors and was therefore proposed as a new therapeutic target for the
treatment of hypoxic tumors. Recently, Pacilli et al (2013) reported
that the inhibition of the CPT1A in vivo models of Burkitt’s
lymphoma induced lipid accumulation in cytosol and reduced the
availability of cytosolic acetyl-CoA. It should also be noted that the
level of acetyl-CoA in a cell regulates the oxidation of fatty acids
and pyruvate (Pekala et al, 2011) and effects the activity of pyruvate
dehydrogenase (PDH) complex that provides the link between
glycolysis and the TCA cycle. The usage of L-carnitine antimetabo-
lites, and eventual inhibition of the b-oxidation, may also result in a
decrease in cytosolic NADPH production. Decreased level of NADPH
in the cytosol results in increased production of reactive oxygen
species resulting in cell death within HCC tumor as in glioma cells
(Pike et al, 2011).
In conclusion, we identified potential antimetabolites which may
inhibit the growth of HCC tumors through the use of personalized
metabolic modeling, proposed the usage of antimetabolites for the
treatment of HCC, and demonstrated the inhibitory effect of the
L-carnitine analog, one of the predicted antimetabolites, on the prolif-
eration of the HepG2 cell line. The results of our study can be used
to reduce the number of chemical compounds for drug screening by
focusing on the structural analogs of the identified antimetabolites.
It is of course important to note that the findings presented here are
based on cellular models and do not take systemic effects into
consideration. One way to alleviate this could be to integrate the
method described here with whole-body pharmacokinetic and phar-
macodynamics modeling. Beyond the prediction of new potential
drug targets for HCC, the modeling approach presented here may be
expanded to predict the effect of a standard therapy for a particular
individual and evaluate whether the treatment is likely to work.
Our approach may hereby enable new exciting possibilities for
personalized medicine.
Materials and Methods
Proteomics data for HCC patients
The HPA portal covers the relative abundance of proteins analyzed
with one or more antibodies and the subcellular localization of
proteins in all major human healthy cells and cancer (Uhlen et al,
2010). The proteomic profiling using immunohistochemistry was
performed as previously described (Uhlen et al, 2005). In brief,
tissue microarrays (TMAs) were produced for HCC tumors obtained
from 27 different HCC patients. Representative formalin- and
A
B
C
Figure 7. Inhibitory effect of perhexiline on the proliferation of the
HepG2 cell line.
A, B Perhexiline was used to mimic the effect of the L-carnitine analog on the
proliferation of the HepG2 cell line. The number of viable cells was
determined after treatment with (A) perhexiline (2, 4, 8, and 20 lM) and
(B) sorafenib (2 and 4 lM) for 24 and 48 h. Both perhexiline and
sorafenib were dissolved in DMSO, and for each concentration of
compounds analyzed, controls with corresponding concentration of
DMSO were analyzed. Each bar represents the results from eight
replicate samples, and mean  s.d. values are presented. Students
t-test versus untreated cells: *P-values < 0.001.
C Example images for the HepG2 cell line after 24 h of the treatment with
20 lM perhexiline and corresponding concentration of DMSO.
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paraffin-embedded material from donor blocks were punched
(1 mm in diameter) and placed in a recipient block TMAs (Kampf
et al, 2012). Thereafter, 4-lm TMA sections were cut using a micro-
tome and placed on super frost glass slides.
Immunohistochemically stained tissues were scanned and digital-
ized at 20× magnification. Annotations of each high-resolution
image was manually performed by certified pathologists with the
relative expression levels including strong, moderate, weak, and
negative (Kampf et al, 2004), and proteins with strong, moderate,
and weak relative expression were included in the reconstruction
process of the GEMs. The annotation of the presence or absence of a
particular protein target as well as related high-resolution images is
publically available through the Human Protein Atlas (www.pro-
teinatlas.org). During the reconstruction process of personalized
GEM for six HCC patients, the missing expression of protein in each
patient was predicted using the median of the protein expression
levels in other 26 HCC patients. The present and absent proteins in
each patient which were input for tINIT are presented in Supple-
mentary Dataset S5.
Task-driven reconstruction using tINIT
Previously, Agren et al (2012) developed the INIT (Integrative
Network Inference for Tissues) algorithm for automated generation
of cell type-specific and cancer GEMs. These networks could be seen
as snapshots of active metabolism in a given cell type, but they were
not functional models that could be directly applied for simulations.
In this work, we expanded significantly the INIT algorithm in order
to allow for direct reconstruction of functional GEMs. The tINIT
algorithm allows the user to define metabolic tasks, which the
resulting model should be able to perform. These metabolic tasks
can be outlined and used as an input to tINIT algorithm in Microsoft
Excel for convenience (Supplementary Dataset S7).
The algorithm then works by first identifying the set of reactions
in the generic model which, if any of them are excluded, cause one
or more of the tasks to fail. This set of reactions then have to be in
the resulting model. Note that this is not the same thing as the
smallest set required for performing the tasks, as there can be iso-
enzymes or alternative pathways. The INIT algorithm is then
implemented as described in the original paper (Agren et al, 2012),
but with the additional constraint that these reactions have to be in
the solution. The resulting solution has to adjust to fit with these
reactions and is therefore likely to be close to being able to
perform the tasks. In a final step, each task is tested in a sequential
manner, and if it cannot be performed, then the gap-filling algo-
rithm in the RAVEN Toolbox (Agren et al, 2013) is applied in order
to enable it. The sequential testing means that the order of the
tasks could theoretically impact which reactions are included in the
gap-filling step. However, this is normally not the case, since the
solution is close to functional because of the set of required
reactions.
tINIT contains two additional improvements over the original
INIT algorithm. Firstly, it constrains the solution so that reversible
reactions cannot have flux in both directions simultaneously. This
enabled some loops to be included even though they were not
connected to the rest of the metabolic network. Secondly, it allows
the user the choice of whether net production of all metabolites
should be allowed (which was the case in the original implementa-
tion). The tINIT algorithm is implemented and extensively
commented in the RAVEN Toolbox (Agren et al, 2013) together with
functions for working with the concept of metabolic tasks
(www.sysbio.se/BioMet).
The tasks used for imposing constraints on the functionality of
the reconstructed models (see Supplementary Dataset S7) are based
on metabolic functions that are known to occur in all cell types. As
such, there is some redundancy between the tasks. For example,
ADP re-phosphorylation is a prerequisite for the biosynthesis of
some of the precursors (which in turn is a prerequisite for biomass
formation). The reason for this is twofold. On the one hand, it
makes for a less computationally demanding optimization, as the
reconstruction can be performed in a more stepwise manner. On the
other hand, it makes for more fine-grained analysis of the impact of
each task, in particular when it comes to the effect of antimetabo-
lites. It should be noted that the redundancy is not a problem from a
reconstruction viewpoint, since the resulting GEM will look the
same regardless.
Since the set of measured proteins differed somewhat between
the six HCC patients, averaged data from all 27 HCC patients
were used to fill the gaps. tINIT requires that all reactions in the
reference network are given a score, and the alternative solution
would be to use an arbitrary negative score for proteins which
were not measured in some given patient. This would represent a
larger bias, and it was therefore chosen that averaged data should
be used for the missing protein expression value. It should be
also noted that the filled protein expression data are relatively
small comparing to the measured protein expressions in each
patient.
Prediction of antimetabolites and their toxicity
The effect of antimetabolites was emulated by considering the corre-
sponding real metabolites as antimetabolite analogs. For each
unique metabolite (not taking compartmentalization into account),
all reactions that used it as a substrate were constrained to have no
flux. Reversible reactions were constrained to have no flux in the
direction where the metabolite was a substrate. The model was then
tested for its ability to perform each of the 56 tasks defined in
Supplementary Dataset S7 by using the checkTasks function in the
RAVEN Toolbox. This was done for each of the six HCC models and
for the 83 GEMs for healthy cell types.
In total, 3,160 metabolites were tested in this manner, out of
which 410 disabled growth in at least one of the HCC models (Sup-
plementary Dataset S10). 349 out of these disabled growth in all six
HCC models and this led to a total of 349 potential antimetabolites.
However, a large fraction of these were fatty acid derivatives
involved in the formation of pool metabolites. These were deemed
to be unlikely to be effective antimetabolites and were thus
excluded. This resulted in a final list of 147 metabolites that are
potential antimetabolite homologs. One hundred and one of these
potential antimetabolites were effective in killing the growth of the
tumors in all six HCC patients.
Antimetabolites can also be disruptive to healthy cells, similar to
other chemotherapeutic drugs (Munoz-Pinedo et al, 2012). It is
therefore a need for evaluating the toxic effect on health cells. We
used the 83 GEMs for healthy cells as a means to investigate this. As
a first step, metabolites which disabled tasks classified as being
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involved in energy and redox balancing in any of the 83 GEMs for
healthy cells were excluded. The rational for this was that such
tasks could be supposed to be central for all types of cells, not only
proliferating ones.
Cell proliferation assay on liver cancer cell line HepG2
Hepatocellular carcinoma cell line HepG2 was obtained from DSMZ
(DSMZ, Braunschweig, Germany) and cultivated according to
DSMZ instructions. A proliferation assay was performed using the
colorimetric CellTiter 96 AQueous One Solution Cell Proliferation
Assay (MTS) (Promega, Fitchburg, USA) according to instructions
from the manufacturer. In brief, HepG2 was separately treated with
2 and 4 lM of sorafenib (Santa Cruz Biotechnology, Inc., Dallas,
USA) and with 2, 4, 8, and 20 lM of perhexiline maleate salt
(Sigma-Aldrich, St. Louis, USA) for 24 and 48 h. Both compounds
were dissolved in DMSO, and corresponding concentrations of
DMSO in the medium were used as controls. In addition, controls
consisting of cells growing in only cell culture medium were
included. For all concentrations of sorafenib and perhexiline male-
ate salt, and for corresponding DMSO controls, eight replicates were
analyzed. For the controls consisting of cells in only medium, 16
replicates were analyzed. For all experiments, the measured colori-
metric differences between DMSO controls and medium controls
were insignificant.
Supplementary information for this article is available online:
http://msb.embopress.org
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